Split History
PLXP split history picture
PLx Pharma (PLXP) has 1 split in our PLXP split history database. The split for PLXP took place on April 20, 2017. This was a 1 for 8 reverse split, meaning for each 8 shares of PLXP owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 125 share position following the split.

When a company such as PLx Pharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the PLXP split history from start to finish, an original position size of 1000 shares would have turned into 125 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into PLx Pharma shares, starting with a $10,000 purchase of PLXP, presented on a split-history-adjusted basis factoring in the complete PLXP split history. PLXP split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 03/14/2014
End date: 01/28/2022
Start price/share: $107.20
End price/share: $5.71
Dividends collected/share: $0.00
Total return: -94.67%
Average Annual Total Return: -31.07%
Starting investment: $10,000.00
Ending investment: $532.48
Years: 7.88
PLx Pharma is a pharmaceutical company focused on its PLxGuard drug delivery platform. Co.'s PLxGuard delivery system targets the release of active pharmaceutical ingredients to various portions of the gastrointestinal tract. Co.'s primary product, VAZALORE 325 mg, has been approved by the FDA for liquid-filled aspirin capsule. In clinical trials in obese diabetic patients at risk for cardiovascular disease, VAZALORE 325 mg delivered platelet inhibition consistent with immediate release aspirin. VAZALORE 81 mg is Co.'s lower-dose companion product for VAZALORE 325 mg. This product utilizes the same formulation as the 325 mg product (except delivered in a capsule one quarter the size). According to our PLXP split history records, PLx Pharma has had 1 split.
Date Ratio
04/20/20171 for 8
PLXP is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

PMD Split History
PPHM Split History
PRAN Split History
PRGO Split History
PRPO Split History
PRSN Split History
PRTK Split History
PRXL Split History
PSTI Split History
PTIE Split History

Also explore: PLXP shares outstanding history

Email EnvelopeFree PLXP Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Great Elm Capital Corp. (GECC)
AeroCentury Corp. (ACY)
NAPCO Security Technologies, Inc. (NSSC)
Equitable Group Inc. (EQB.CA)
U.S. Well Services (USWS)
InMode Ltd. (INMD)
Sonim Technologies, Inc. (SONM)
AzurRx BioPharma, Inc. (AZRX)
Jaguar Health, Inc. (JAGX)
Microchip Technology Incorporated (MCHP)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

PLXP Insider Buying

PLXP Split History | www.SplitHistory.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.